Latest news and press releases about Fennec Pharmaceuticals Inc. (FENC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc.
Price
| Price | $10.55 |
| Market Cap | $366M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AARD · AVTX · BDTX · CRBU · ENTA · EPRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of FENC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks